Shineco Inc. (NASDAQ: SISI), a biotechnology company recognized for its advancements in induced pluripotent stem cell (iPSC) research, has entered into a cooperation agreement with blockchain infrastructure firm Plus Me Limited. The partnership is centered on creating a blockchain-based ecosystem for biological cellular assets, where tokenization will enable seamless international transfers, standardized custody, and transparent verification. The initiative introduces what the companies describe as an “Asset On-Chaining plus Application Scenarios” framework, which could reshape the commercial structure of the global cell therapy industry.
According to the agreement, Plus Me will manage the full lifecycle custody of Shineco’s compliant mesenchymal stem cells (MSCs) on the Ethereum mainnet. Asset ownership will be enforced through smart contracts, while each cell unit will receive a unique non-fungible digital identifier to guarantee authenticity and compliance. These measures rely on on-chain hashing to ensure both traceability and regulatory alignment.
Security Tokens and Redemption Mechanism
The tokenization process will be implemented through the issuance of ERC-1400 and ERC-20 compliant security tokens, branded as Cell Infusion Redemption Tokens. These tokens will serve as redeemable instruments within Shineco-affiliated Cell Therapy Centers. Upon redemption, tokens will be programmatically burned, ensuring scarcity and aligning long-term value with stakeholder interests.
This real-world asset tokenization model has been designed to address three major challenges facing the industry: high treatment costs, lack of verifiable provenance, and limited liquidity of biological assets. By converting cell products into digital instruments, Shineco and Plus Me aim to make cellular therapies more accessible, transparent, and tradable on a global scale.
Strategic Infrastructure and Acquisitions
To reinforce the initiative, Shineco has taken majority ownership of Xi’an Dong’ao Health Management Co., Ltd., acquiring a 51 percent stake as of August 18, 2025. The company specializes in cryogenic cell storage and clinical applications, providing the off-chain infrastructure necessary for token redemption. This acquisition adds to Shineco’s earlier purchase of Singapore-based Infiniclone, giving the company operational control over a worldwide storage and infusion network. The integrated infrastructure is expected to enable smooth on-chain and off-chain settlement of tokenized biological assets.
The cooperation also involves joint ecosystem development, with Shineco opening its custody network to third parties while Plus Me provides tokenization software-as-a-service. Shineco will continue to oversee biological quality assurance off-chain, while Plus Me manages regulatory compliance on-chain. The model aims to create cross-border synergies, including partnerships with organizations such as Singapore’s ACTRIS. By combining infrastructure with compliance, Shineco is positioning itself as a global infrastructure provider for the emerging cell economy, with scalability at the core of its strategy.
Toward a Decentralized Biotech Economy
Shineco’s leadership views the agreement as part of a broader shift within biotechnology from clinical trials to commercial expansion. The initiative has been described as the beginning of a decentralized biotech economy in which each cell becomes a programmable, liquid asset capable of unlocking new value for both medicine and investors. Token holders will gain governance rights and, in future stages, may participate in decentralized autonomous organization (DAO) voting to help shape global ecosystem development.
Plus Me will provide the blockchain middleware required for the system, including compliance tools, tokenomics architecture, and cross-border liquidity solutions. The firm also works with global exchanges to enable token deployment and secondary market activity. On the other hand, Xi’an Dong’ao Health will continue its role in GMP-compliant storage and clinical applications, focusing on health management protocols that integrate prevention, intervention, and long-term maintenance.
Industry Implications
The combined framework is expected to redefine how cellular therapies are commercialized, bringing together biotechnology and blockchain into a unified ecosystem. By addressing core issues of trust, cost, and liquidity, Shineco and Plus Me are positioning themselves at the forefront of a model that could accelerate global adoption of cell-based therapies. If successful, the initiative may establish a blueprint for integrating real-world biological assets with programmable financial instruments, creating new opportunities for innovation, investment, and patient care.